Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
Abbott (NYSE: ABT) announced FDA approval of its Volt™ Pulsed Field Ablation (PFA) System to treat atrial fibrillation on Dec 22, 2025. Approval was based on the VOLT-AF IDE study of 392 patients across 40 centers in the U.S., Europe, Canada and Australia, showing clinically meaningful safety and effectiveness for both paroxysmal and persistent AFib. Volt is an all-in-one PFA catheter with a proprietary balloon-in-basket design, integration with Abbott’s EnSite X mapping system, fewer therapy applications, reduced fluoroscopy, and the option for procedures under conscious sedation. Abbott will begin U.S. commercial cases and continue EU site expansion.
Abbott (NYSE: ABT) announced FDA clearance and CE Mark for the Amplatzer Piccolo Delivery System to be used with the Amplatzer Piccolo Occluder to treat patent ductus arteriosus (PDA) in premature infants.
The delivery system is designed for the tiniest babies (some as small as ~2 pounds), enables single-catheter procedures, and aims to improve placement precision and reduce adverse events. The Amplatzer Piccolo Occluder was previously approved in 2019. The announcement highlights Abbott's pediatric structural heart portfolio and provides links for important safety information.
Abbott (NYSE: ABT) announced a 6.8% increase in its quarterly common dividend to $0.63 per share. The dividend is payable Feb. 13, 2026 to shareholders of record at the close of business on Jan. 15, 2026.
This raises the company's quarterly payout more than 70% since 2020, marks Abbott's 54th consecutive year of dividend growth and is the 408th consecutive quarterly dividend paid since 1924. Abbott remains a member of the S&P 500 Dividend Aristocrats.
Abbott (NYSE: ABT) announced Lingo, its over-the-counter continuous glucose monitor and app, is now available on Android, expanding access beyond iOS in the U.S. and U.K.
Lingo is intended for adults 18+ not using insulin and offers real-time glucose data and a daily metric, Lingo Count, to quantify glucose spikes. Abbott reported that reducing Lingo Count over about three months halves time above the healthy range and lowers average glucose by 10%. Real-world data showed protein supplementation days had 15% lower odds of glucose spikes and a 2 mg/dL average glucose reduction ( 18% odds and 3 mg/dL reduction among people with obesity).
Abbott (NYSE: ABT) and the Big Ten reported that the second annual "We Give Blood" drive (Aug. 27–Dec. 5, 2025) produced 83,043 donations, a 319% increase versus 2024, and could help save up to 250,000 lives. The University of Wisconsin led with 15,476 donations and will receive a $1 million Abbott award to advance student or community health. Student donors rose 168%, with 92% of participants saying they are likely to donate again. The campaign aimed to address a national blood shortage and boost younger donor participation.
Abbott (NYSE: ABT) on Dec. 4, 2025 launched two Ensure Max Protein shakes aimed at muscle health: Ensure Max Protein 42g for active adults (42 g protein, 23 vitamins/minerals, 2 electrolytes, 2 g sugar, 220 calories) and Ensure Max Protein 2 in 1 Muscle Support for older adults (30 g protein, 1.5 g CaHMB, 26 vitamins/minerals). Abbott cited muscle loss after age 40 and described HMB research spanning 25+ years. Real-world data from >9,500 users of Abbott's Lingo continuous glucose monitor found 15% lower odds of elevated glucose on days users consumed protein shakes. The products are exclusive at Walmart through March 2026, with wider retail distribution beginning April 2026.
Abbott (NYSE: ABT) agreed to acquire Exact Sciences (NASDAQ: EXAS) for $105 per share, implying approximately $21 billion equity value and an estimated $23 billion enterprise value; Abbott will absorb about $1.8 billion of Exact Sciences net debt. Exact Sciences is projected to generate more than $3 billion in revenue this year with high‑teens organic growth and brings leading assets including Cologuard, Oncotype DX, Oncodetect and Cancerguard. Abbott expects the deal to be immediately accretive to revenue growth and gross margin. Closing is expected in Q2 2026, subject to shareholder and regulatory approvals.
Abbott (NYSE: ABT) and Hallmark Channel partner on a new holiday film, "The More the Merrier", which premieres Friday, Nov. 28, 2025 at 8 p.m. ET/PST and streams on Hallmark+ the following day. The movie features real members of Abbott HeartMates — a support community for people affected by heart conditions — and includes cameos by HeartMates ambassador Damar Hamlin.
The story centers on a 14-year-old heart patient inspired by HeartMates member Zeke Mankins; other featured members include Tony Daly, Jaden Hartley, Rian Krauth, and MacKenzie Maddry. Abbott cardiologists consulted on the script for medical accuracy. Safety links for specific Abbott devices are provided for U.S. audiences.
Abbott (NYSE: ABT) reported 3Q25 sales $11.37B, up 6.9% reported and 5.5% organic (or 7.5% organic excluding COVID‑19 tests). 3Q GAAP diluted EPS was $0.94; adjusted diluted EPS was $1.30. Reported operating margin was 18.1%; adjusted operating margin was 23.0% (+40 bps).
Medical Devices led growth: +14.8% reported and Diabetes Care CGM sales were $2.0B (+20.5% reported). Diagnostics declined: −6.6% reported (COVID testing sales $69M vs. $265M prior year). Abbott reaffirmed full‑year 2025 organic sales guidance and narrowed adjusted EPS range to $5.12–$5.18.
Abbott (NYSE:ABT) has scheduled its third-quarter 2025 financial results announcement for Wednesday, October 15, 2025, before market opening. The company will host a live earnings conference call at 8 a.m. Central time (9 a.m. Eastern). Investors can access the webcast through Abbott's Investor Relations website. An archived version of the call will be made available later the same day.